Incidence of neutropenia induced by chemotherapy in the treatment of colorectal cancer
DOI:
https://doi.org/10.15253/2175-6783.20192033884Keywords:
Neutropenia, Colorectal Neoplasms, Incidence, Epidemiology, Antineoplastic Combined Chemotherapy Protocols.Abstract
Objective: to analyze the incidence of neutropenia in patients with colorectal cancer, undergoing chemotherapy treatment. Methods: integrative review performed in the following databases: National Library of Medicine, National Institutes of Health, Cumulative Index to Nursing and Allied Health Literature, Latin American literature and Caribbean Center in Health Sciences, and SciVerse Scopus. Results: 499 articles were identified, of which 15 met the criteria for inclusion, published between 2006 and 2016 and analyzed in their entirety. Neutropenia was the most reported hematologic toxicity in 12 (80.0%) studies, and the second most common in three (20.0%), in varying degrees, being responsible for reducing and/or delaying of doses in six (40.0%) studies. Conclusion: the studies included in this review showed that neutropenia in patients with colorectal cancer in chemotherapy treatment have low incidences in different degrees, despite the significantly high rates of neutropenia associations, as the most common adverse event in the various analyzed regimes.
References
Freire MEM, Costa SFG, Lima RAG, Sawada NO. Health-related quality of life of patients with cancer in palliative care. Text Contexto Enferm. 2018; 27(2):1-13. doi: http://dx.doi.org/10.1590/0104-070720180005420016
Nicolussi AC, Sawada NO, Cardozo FMC, Andrade V, Paula JM. Health-related quality of life of câncer patients undergoing chemotherapy. Rev Rene. 2014; 15(1):132-40. doi: http://dx.doi.org/10.15253/2175-6783.2014000100017
Toneti BF, Paula JM, Nicolussi AC, Sawada NO. Health-related quality of life of the elderly with cancer in adjuvant treatment. Rev Rene. 2014; 15(6):1030-8. doi: http://dx.doi.org/10.15253/2175-6783.2014000600017
Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, et al. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015; 15:786. doi: http://doi.org/10.1186/s12885-015-1712-0
Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer. 2012; 12:271. doi: http://doi.org/10.1186/1471-2407-12-271
Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, et al. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci. 2012; 103(8):1502-7. doi: https://doi.org/10.1111/j.1349-7006.2012.02320.x
Martins AVC, Didier MEV. Neutropenia febril. In: Fonseca RP, Coelho OFL. Urgências oncológicas no pronto-socorro: uma abordagem para o clínico. São Paulo: Atheneu; 2015. p.187-96.
Yoshida Y, Hoshino S, Aisu N, Mogi A, Yamada T, Kojima D, et al. Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? Support Care Cancer. 2015; 23(6):1623-7. doi: https://doi.org/10.1007/s00520-014-2518-3
Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm. 2008; 17(4):756-64. doi: http://dx.doi.org/10.1590/S0104-07072008000400018
Fineout-Overholt E, Stillwell SB. Asking compelling, clinical questions. In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare: a guide to best practice [Internet]. 2011 [cited Jan. 19, 2019]. Available from: http://file.zums.ac.ir/ebook/208-Evidence-Based%20Practice%20in%20Nursing%20&%20Healthcare%20-%20A%20Guide%20to%20Best%20Practice,%20Second%20Edition-Be.pdf
Ursi ES, Galvão CM. Prevenção de lesões de pele no perioperatório: revisão integrativa da literatura. Rev Latino-Am Enfermagem. 2006; 14(1):124-31. doi: http://dx.doi.org/10.1590/S0104-11692006000100017
Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009; 6(6):e1000097. doi: https://doi.org/10.1371/journal.pmed.1000097
Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, et al. A phase ii clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol. 2013; 43(11):1080-6. doi: https://doi.org/10.1093/jjco/hyt127
Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013; 13:611. doi: https://doi.org/10.1186/1471-2407-13-611
Uygyn K, Bilici A. Kaya S, Ustaalioglu BBO, Yildiz R, Temiz S, et al. Xeliri plus bevacizumab compared with folfiri plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev. 2013; 14(4):2283-8. doi: http://dx.doi.org/10.7314/APJCP.2013.14.4.2283
Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77(2):113-9. doi: https://doi.org/10.1159/000229787
Shigeta K, Hasegawa H, Okabayashi K, Tsuruta M, Ishii Y, Endo T, et al. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Int J Cancer. 2016; 139(4):946-54. doi: https://doi.org/10.1002/ijc.30127
Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience. Clin Colorectal Cancer. 2014; 13(3):199-206. doi: https://doi.org/10.1016/j.clcc.2014.06.002
Roque VMN, Forones NM. Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas. Arq Gastroenterol. 2006; 43(2):94-101. doi: http://dx.doi.org/10.1590/S0004-28032006000200007
Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Ito Y, et al. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. Asia Pac J Clin Oncol. 2015; 13(2):132-7. doi: https://doi.org/10.1111/ajco.12405
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Eng J Med. 2014; 371(17):1609-18. doi: https://doi.org/10.1056/NEJMoa1403108
Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M et al. Oxaliplatin/fl uorouracil/leucovorin (FOLFOX4 and modifi ed FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007; 12(3):218-23. doi: http://doi.org/10.1007/s10147-007-0658-x
Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori. 2006; 92(4):290-4. doi: https://doi.org/10.1177/030089160609200405
Huang J, Yen C, You Y, Wang C, Lan Y, Lai C, et al. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study. Chang Gung Med J [Internet]. 2006 [cited 2018 Apr 29]; 29:297-305. Available from: http://cgmj.cgu.edu.tw/2903/290311.pdf
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicenter randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94(6):798-805. doi: https://doi.org/10.1038/sj.bjc.6603011
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of dpyd 2a to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016; 34(3):227-34. doi: https://doi.org/10.1200/JCO.2015.63.1325
Nascimento TG, Andrade M, Oliveira RA, Almeida AM, Gozzo TO. Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy. Rev Latino-Am Enfermagem. 2014; 22(2):301-8. doi: http://dx.doi.org/10.1590/0104-1169.3305.2416
Tan X, Wen Q, Wang R, Chen Z. Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies. Expert Rev Anticancer Ther. 2017; 17(11):1077-85. doi: http://dx.doi.org/10.1080/14737140.2017.1380521
Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capeci- tabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer. 2009; 100(11):1720-4. doi: https://doi.org/10.1038/sj.bjc.6605075
Koutras AK, Kalofonos HP. Myelotoxicity in cancer patients treated with chemotherapy: negative or positive prognostic factor? Clin Cancer Res. 2008; 14(22):7579. doi: https://doi.org/10.1158/1078-0432.CCR-08-1519
